FIL1h anticorps

N° du produit ABIN5564286

Détail du produit anti-FIL1h anticorps

Antigène: FIL1h (Interleukin 1 eta (FIL1h))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FIL1h est non-conjugé

Application: Western Blotting (WB), ELISA

Specificité: Recognizes human IL-36beta.

Réactivité croisée: Humain

Aucune reactivité croisée: Souris

Réactivité croisée (Details): Does not cross-react with mouse IL-36beta and IL-36gamma.

Immunogène: Recombinant human IL-36beta.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Date de péremption: 12 months

Détails sur FIL1h

Antigène: FIL1h (Interleukin 1 eta (FIL1h))

Autre désignation: IL-36beta (FIL1h Produits)

Synonymes: anticorps 2310043N20Rik, anticorps Il36b, anticorps FIL1, anticorps FIL1-(ETA), anticorps FIL1H, anticorps FILI-(ETA), anticorps IL-1F8, anticorps IL-1H2, anticorps IL1-ETA, anticorps IL1F8, anticorps IL1H2, anticorps Il1f8, anticorps interleukin 1 family, member 8, anticorps interleukin 36 beta, anticorps interleukin 36, beta, anticorps Il1f8, anticorps IL36B, anticorps Il36b

Sujet: IL-36alpha (IL-1F6), IL-36beta (IL-1F8) and IL-36gamma (IL-1F9) bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1. IL-36Ra inhibits the production of proinflammatory cytokines, including IL-12, IL-1beta, IL-6, TNF-alpha and IL-23 induced by IL-36 in BMDC and CD4 T cells. Skin and dendritic cells are targets of the IL-36 interleukins leading to a Th1 response. These cytokines may represent potential targets for immune-mediated inflammatory conditions or, alternatively, could be used as adjuvants in vaccination.